PENTETATE CALCIUM TRISODIUM YB-169

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H18N3O10.Ca.3Na.Yb
Molecular Weight	666.289
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PENTETATE CALCIUM TRISODIUM YB-169

Structure Search

SMILES

[Na+].[Na+].[Na+].[Ca++].[169Yb].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O

InChI

InChIKey=YXZBWJWYWHRIMU-UBPCSPHJSA-I

InChI=1S/C14H23N3O10.Ca.3Na.Yb/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;;;;;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);;;;;/q;+2;3*+1;/p-5/i;;;;;1-4

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Yb
Molecular Weight	168.93518712
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H18N3O10
Molecular Weight	388.3068
Charge	-5
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11786324 | https://aapm.onlinelibrary.wiley.com/doi/abs/10.1118/1.596813 | https://www.ncbi.nlm.nih.gov/pubmed/28940520 | https://www.tabletwise.com/us/ytterbium-yb-169-dtpa-injectable/uses-benefits-working

Yb-169 is a radioisotope of rare-earth element ytterbium. Yb-169 emits gamma-photons with an average energy of 93 keV and decays with a half‐life of 32 days. Yb-169 has an application to brachytherapy. Implants for direction modulated brachytherapy are developed for the treatment of locally advanced cervical cancer. Yb-169 was suggested for the use in intravascular brachytherapy for the treatment of arterial restenosis. An injected complex of Yb-169 with DPTA was used for the treatment of internal contamination with americium, curium, or plutonium and other conditions.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Internal contamination with americium, curium, or plutonium 2 Sources: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017518	Primary		Approved 8583	YTTERBIUM YB 169 DTPA Approved Use Internal contamination with americium, curium, or plutonium Launch Date 1976

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:48:25 GMT 2025` Edited by `admin` on `Mon Mar 31 17:48:25 GMT 2025`
Record UNII	Q6RE2BCW3P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COMPOUND 24266

Preferred Name

English

PENTETATE CALCIUM TRISODIUM YB-169

Official Name

English

PENTETATE CALCIUM TRISODIUM YB 169 [USAN]

Common Name

English

PENTETATE CALCIUM TRISODIUM YB-169 [ORANGE BOOK]

Common Name

English

YTTERBIUM YB-169 PENTETATE TRISODIUM CALCIUM

Common Name

English

COMPOUND-24266

Code

English

MATERIAL-A

Code

English

YTTERBIUM YB-169 DTPA

Common Name

English

CALCIATE(3-), (N,N-BIS(2-(BIS(CARBOXYMETHYL)AMINO)ETHYL)GLYCINATO(5-))-, TRISODIUM, LABELED WITH YTTERBIUM-169

Common Name

English

Trisodium [N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]calciate(3-), labeled with ytterbium-169

Common Name

English

MRP-10

Code

English

MATERIAL A

Code

English

Code System Code Type Description

NCI_THESAURUS

C174872